Identification of an Ara-C resistance-related gene risk score and the role of S100A4 in AML via NR6A1-dependent activation and p53 regulation
Authors:
Open Access
- 13 June 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1574759
Abstract
Indroduction: Ara‐C (cytarabine) resistance remains a significant contributor to the poor clinical outcomes in adult acute myeloid leukemia (AML). However, predicting Ara‐C resistance and developing effective targeted therapies remain challenging.Methods: In this study, we integrated transcriptional data from Ara‐C‐resistant cell lines in the GEO database and the TCGA‐LAML cohort to establish an Ara‐C resistancerelated gene risk score (ARRGRS). Kaplan‐Meier survival analysis revealed that AML patients with high ARRGRS had significantly worse prognosis compared to those with low ARRGRS in both cohorts. Additionally, ARRGRS effectively predicted chemotherapy response in AML patients across both cohorts. To further elucidate the mechanisms underlying Ara‐C resistance, we constructed Ara‐C‐resistant AML cell lines and validated our findings using qPCR, Western blotting, flow cytometry (FCM), and in vivo experiments.Results: We discovered that high expression of S100A4 promotes Ara‐C resistance in AML. Mechanistically, we identified that the transcription factor NR6A1 directly binds to the S100A4 promoter, enhancing its transcriptional activity. Subsequently, S100A4 upregulates p53 expression, thereby promoting AML cell proliferation and resistance to Ara‐C.Discussion: In summary, our comprehensive investigation of the ARRGRS not only deepens the understanding of Ara‐C resistance mechanisms but also provides promising insights for targeting S100A4 to inhibit tumor growth and overcome chemotherapy resistance in AML.Keywords
This publication has 39 references indexed in Scilit:
- Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapyLeukemia Research, 2024
- AML treatment: conventional chemotherapy and emerging novel agentsTrends in Pharmacological Sciences, 2024
- Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid LeukemiaJAMA Oncology, 2023
- The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpressionJournal of the Formosan Medical Association, 2022
- Moving toward individualized target-based therapies in acute myeloid leukemiaAnnals of Oncology, 2022
- Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsAmerican Journal of Hematology, 2022
- Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2022
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialThe Lancet Haematology, 2021
- Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemiaLeukemia, 2019
- Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cellsBiochemical Pharmacology, 2009